Comparison of the Effects of Metoprolol and Bisoprolol on Lipid and Glucose Profiles in Cardiovascular Patients

Author(s): Ahmad Abdulrahman Almeman*, Yasir Ahmed Beshir, Ahmad Hamad Aldosary.

Journal Name: Current Drug Safety

Volume 14 , Issue 1 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Cardioselective beta-blockers may affect glucose or lipid profiles.

Objective: We sought to compare the effects of two beta-blockers, metoprolol and bisoprolol, as the most commonly used drugs in cardiology, on glucose and lipid profiles in patients with cardiovascular diseases.

Methods: We conducted a retrospective cross-sectional matched study at Prince Sultan Cardiac Center in Burydah in August 2017. Patient records were screened, and adult patients with cardiovascular disorders who were treated with a stable dose of metoprolol or bisoprolol were included. Parameters related to glucose and lipid metabolism were compared using the Student’s t-test between the two groups.

Results and Conclusion: The metoprolol and bisoprolol arms included 204 and 200 patients, respectively.

Keywords: Metoprolol, bisoprolol, triglycerides, glucose, lipid, triglyceride.

[1]
Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol 2007; 120: 10-27.
[2]
Fonseca VA. Effects of β-blockers on glucose and lipid metabolism. Curr Med Res Opin 2010; 26: 615-29.
[3]
Dorian P, Angaran P. β-Blockers and atrial fibrillation: Hypertension and other medical conditions influencing their use. Can J Cardiol 2014; 30: S38-41.
[4]
Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122: 133-41.
[5]
Kittisupamongkol W. Effect of beta blockers on patient’s lipid profiles. Am Fam Physician 2010; 81: 838-40.
[6]
Weir MR, Moser M. Diuretics and β-blockers: Is there a risk for dyslipidemia? Am Heart J 2000; 139: 174-84.
[7]
Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press 1992; 1: 92-101.
[8]
Haneda T, Ido A, Fujikane T, et al. Effect of bisoprolol, a beta 1-selective beta-blocker, on lipid and glucose metabolism and quality of life in elderly patients with essential hypertension. Nippon Ronen Igakkai Zasshi 1998; 35: 33-8.
[9]
Kantola I, Kontro M, Vesalainen R, Tarssanen L. P-221: Both atenolol and metoprolol have favourable effects on ECG parameters before, during and after exercise in healthy controls. Am J Hypertens 2004; 17: 113A-4A.
[10]
Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-72.
[11]
Chrysant SG, Chappel C, Farnham DJ, et al. Antihypertensive and metabolic effects of single and combined atenolol regimens. J Clin Pharmacol 1992; 32: 61-5.
[12]
Sourgens H, Schmidt J, Derendorf H. Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study. Int J Clin Pharmacol Ther 2003; 41: 22-9.
[13]
Deedwania P. Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: Benefits of vasodilating β-blockers. J Clin Hypertens 2011; 13: 52-9.
[14]
Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. J Assoc Physicians 2006; 99: 431-6.
[15]
Taylor AA, Bakris GL. The role of vasodilating beta-blockers in patients with hypertension and the cardiometabolic syndrome. Am J Med 2010; 123: S21-6.
[16]
Pederson ME, Cockroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep 2007; 9: 269-77.
[17]
Jacob S, Klimm HJ, Rett K, Helsberg K, Haring HU, Godicke J. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004; 112: 315-22.
[18]
Owada A, Suda S, Hata T, Miyake S. The effects of bisoprolol, a selective beta 1-blocker, on glucose metabolism by long-term administration in essential hypertension. Clin Exp Hypertens 2001; 23: 305-16.
[19]
Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. JAMA 2004; 292: 2227-36.
[20]
Garcia-Puig J, Ruilope LM, Luque M, et al. Glucose metabolism in patients with essential hypertension. Am J Med 2006; 119: 318-26.
[21]
Wolinsky H. The effects of beta-adrenergic blocking agents on blood lipid levels. Clin Cardiol 1987; 10: 561-6.
[22]
Szollar LG, Meszaros I, Tornoci L, Rischak K, Molnar M, Manyai S. Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females. J Cardiovasc Pharmacol 1990; 15: 911-7.
[23]
Frithz G, Weiner L. Long-term effects of bisoprolol on blood pressure, serum lipids, and HDL-cholesterol in patients with essential hypertension. J Cardiovasc Pharmacol 1986; 8: S134-8.
[24]
Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 2005; 26: 1585-95.
[25]
Tamargo J, Rosano G, Walther T, et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J Cardiovasc Pharmacother 2017; 3: 163-82.
[26]
Kotecha D, Manzano L, Krum H, et al. Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: Individual patient data meta-analysis. BMJ 2016; 353: i1855.
[27]
Halperin RO, Sesso HD, Ma J, Buring JE, Stampfer MJ, Gaziano JM. Dyslipidemia and the risk of incident hypertension in men. Hypertension 2006; 47: 45-50.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 1
Year: 2019
Page: [27 - 30]
Pages: 4
DOI: 10.2174/1574886313666181029101247

Article Metrics

PDF: 44
HTML: 12
EPUB: 1
PRC: 1